Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest

Biochemical Pharmacology

Volumn 73, Issue 4, 2007, Pages 481-490

  Duan, Lingling ^a   Sterba, Kristen ^a   Kolomeichuk, Sergey ^a   Kim, Heetae ^b   Brown, Powel H ^b   Chambers, Timothy C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AP 1; Apoptosis; c Jun; Senescence; TAM 67; Vinblastine

Indexed keywords

INDUCIBLE C JUN PROTEIN; ISOPROTEIN; PROTEIN C JUN; PROTEIN TAM 67; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; G2 PHASE; HUMANS; IMMUNOBLOTTING; MITOSIS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TUBULIN MODULATORS; VINBLASTINE;

EID: 33845939532     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.026     Document Type: Article

References (25)

1. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
2. Kroemer G., El-Deiry W.S., Golstein P., Peter M.E., Vaux D., Vandenabeele P., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12 (2005) 1463-1467
3. Castedo M., Perfettini J.L., Roumier T., Valent A., Raslova H., Yakushijin K., et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23 (2004) 4362-4370
4. Kops G.J., Weaver B.A., and Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5 (2005) 773-785
5. Shay J.W., and Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004) 2919-2933
6. Fan M., Goodwin M.E., Birrer M.J., and Chambers T.C. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 61 (2001) 4450-4458
7. Berry A., Goodwin M., Moran C.L., and Chambers T.C. AP-1 activation and altered AP-1 composition in association with increased phosphorylation and expression of specific Jun and Fos family proteins induced by vinblastine in KB-3 cells. Biochem Pharmacol 62 (2001) 581-591
8. Brantley-Finley C., Lyle C.S., Du L., Goodwin M.E., Hall T., Szwedo D., et al. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66 (2003) 459-469
9. Obey T.B., Lyle C.S., and Chambers T.C. Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine. Biochem Biophys Res Commun 335 (2005) 1179-1184
10. Ludes-Meyers J.H., Liu Y., Munoz-Medellin D., Hilsenbeck S.G., and Brown P.H. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20 (2001) 2771-2780
11. Upreti M., Lyle C.S., Skaug B., Du L., and Chambers T.C. Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members. J Biol Chem 281 (2006) 15941-15950
12. Brown P.H., Chen T.K., and Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9 (1994) 791-799
13. Kallunki T., Deng T., Hibi M., and Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87 (1996) 929-939
14. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072 (1991) 129-157
15. Schreiber M., Kolbus A., Piu F., Szabowski A., Mohle-Steinlein U., Tian J., et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13 (1999) 607-619
16. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
17. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
18. Shaulian E., Schreiber M., Piu F., Beeche M., Wagner E.F., and Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 103 (2000) 897-907
19. Sherwood S.W., Sheridan J.P., and Schimke R.T. Induction of apoptosis by the anti-tubulin drug colcemid: relationship of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells. Exp Cell Res 215 (1994) 373-379
20. Woods C.M., Zhu J., McQueney P.A., Bollag D., and Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1 (1995) 506-526
21. Sorger P.K., Dobles M., Tournebize R., and Hyman A.A. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 9 (1997) 807-814
22. Casenghi M., Mangiacasale R., Tuynder M., Caillet-Fauquet P., Elhajouji A., Lavia P., et al. p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res 250 (1999) 339-350
23. Lanni J.S., and Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18 (1998) 1055-1064
24. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59 (1999) 3761-3767
25. Kinoshita I., Leaner V., Katabami M., Manzano R.G., Dent P., Sabichi A., et al. Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth. Oncogene 22 (2003) 2710-2722